446 related articles for article (PubMed ID: 23666920)
1. LMNA-associated cardiocutaneous progeria: an inherited autosomal dominant premature aging syndrome with late onset.
Kane MS; Lindsay ME; Judge DP; Barrowman J; Ap Rhys C; Simonson L; Dietz HC; Michaelis S
Am J Med Genet A; 2013 Jul; 161A(7):1599-611. PubMed ID: 23666920
[TBL] [Abstract][Full Text] [Related]
2. The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Odinammadu KO; Shilagardi K; Tuminelli K; Judge DP; Gordon LB; Michaelis S
Nucleus; 2023 Dec; 14(1):2288476. PubMed ID: 38050983
[TBL] [Abstract][Full Text] [Related]
3. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
4. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
5. A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS.
Denecke J; Brune T; Feldhaus T; Robenek H; Kranz C; Auchus RJ; Agarwal AK; Marquardt T
Hum Mutat; 2006 Jun; 27(6):524-31. PubMed ID: 16671095
[TBL] [Abstract][Full Text] [Related]
6. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
McClintock D; Gordon LB; Djabali K
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
[TBL] [Abstract][Full Text] [Related]
7. Hutchinson-Gilford progeria syndrome.
Pollex RL; Hegele RA
Clin Genet; 2004 Nov; 66(5):375-81. PubMed ID: 15479179
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
[TBL] [Abstract][Full Text] [Related]
9. [The role of lamins and mutations of LMNA gene in physiological and premature aging].
Sliwińska MA
Postepy Biochem; 2007; 53(1):46-52. PubMed ID: 17718387
[TBL] [Abstract][Full Text] [Related]
10. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
[TBL] [Abstract][Full Text] [Related]
11. Lamin A-linked progerias: is farnesylation the be all and end all?
Smallwood DT; Shackleton S
Biochem Soc Trans; 2010 Feb; 38(Pt 1):281-6. PubMed ID: 20074075
[TBL] [Abstract][Full Text] [Related]
12. An inherited LMNA gene mutation in atypical Progeria syndrome.
Doubaj Y; De Sandre-Giovannoli A; Vera EV; Navarro CL; Elalaoui SC; Tajir M; Lévy N; Sefiani A
Am J Med Genet A; 2012 Nov; 158A(11):2881-7. PubMed ID: 22991222
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
14. Nuclear Abnormalities in
Wilke MVMB; Wick M; Schwab TL; Starosta RT; Clark KJ; Connolly HM; Klee EW
Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38255001
[TBL] [Abstract][Full Text] [Related]
15. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
16. Truncated prelamin A expression in HGPS-like patients: a transcriptional study.
Barthélémy F; Navarro C; Fayek R; Da Silva N; Roll P; Sigaudy S; Oshima J; Bonne G; Papadopoulou-Legbelou K; Evangeliou AE; Spilioti M; Lemerrer M; Wevers RA; Morava E; Robaglia-Schlupp A; Lévy N; Bartoli M; De Sandre-Giovannoli A
Eur J Hum Genet; 2015 Aug; 23(8):1051-61. PubMed ID: 25649378
[TBL] [Abstract][Full Text] [Related]
17. Prelamin A and ZMPSTE24 in premature and physiological aging.
Worman HJ; Michaelis S
Nucleus; 2023 Dec; 14(1):2270345. PubMed ID: 37885131
[TBL] [Abstract][Full Text] [Related]
18. Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress.
Paradisi M; McClintock D; Boguslavsky RL; Pedicelli C; Worman HJ; Djabali K
BMC Cell Biol; 2005 Jun; 6():27. PubMed ID: 15982412
[TBL] [Abstract][Full Text] [Related]
19. Hutchinson-Gilford progeria syndrome: clinical findings in three patients carrying the G608G mutation in LMNA and review of the literature.
Mazereeuw-Hautier J; Wilson LC; Mohammed S; Smallwood D; Shackleton S; Atherton DJ; Harper JI
Br J Dermatol; 2007 Jun; 156(6):1308-14. PubMed ID: 17459035
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
